This Darzalex Faspro market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to regulatory approvals, the rising prevalence of cancer, the increasing incidence of lifestyle-related diseases, favorable reimbursement policies, and improvements in patient outcomes.
The projected growth in the forecast period is driven by the expanding patient populations, ongoing clinical trials, regulatory expansions, the use of combination therapies, and greater global healthcare access. Key trends during this period include advancements in monoclonal antibody technology, innovations in antibody-drug conjugate development, patient-centric treatments, personalized medicine, and the growing competition from biosimilars.
The increasing incidence of cancer is expected to drive the growth of the darzalex faspro market in the coming years. Cancer encompasses a range of diseases marked by uncontrolled cell growth and spread to other areas of the body. The rising number of cancer cases is influenced by factors such as an aging population, unhealthy lifestyles, environmental exposures, improved detection methods, and genetic factors. Darzalex Faspro plays a significant role in treating cancer, particularly by targeting and depleting CD38-positive cells, which enhances the immune system's ability to combat cancer. This treatment helps manage and reduce the progression of multiple myeloma and other related cancers. For example, the American Cancer Society reported in April 2024 that in 2022, there were 20 million new cancer diagnoses globally, with 9.7 million cancer-related deaths. By 2050, new cancer cases are expected to increase to 35 million. As a result, the growing prevalence of cancer will likely drive the darzalex faspro market forward.
The expansion of global healthcare infrastructure is also expected to contribute to the growth of the darzalex faspro market. Healthcare infrastructure encompasses the necessary structures, resources, and systems required to provide healthcare services. Key drivers of this expansion include an aging global population, the rise in chronic diseases, and advancements in medical technology. Improved healthcare infrastructure is essential for patients who require Darzalex Faspro, as it facilitates access to trained professionals who can administer the subcutaneous injection in outpatient settings, reducing the need for long hospital stays. For instance, according to Cross River Therapy's statistics in September 2024, the U.S. pharmaceutical industry generated $550 billion in revenue in 2021, with Americans spending $576.9 billion on medicine. Projected spending is expected to rise to $605-$635 billion by 2025, highlighting how healthcare infrastructure growth supports the darzalex faspro market.
A key trend in the darzalex faspro market is the focus on regulatory advancements for combination treatments, particularly quadruplet therapy, which is expected to improve treatment outcomes for multiple myeloma patients. Quadruplet therapy involves using four different medications, each targeting different aspects of the disease. In July 2024, Johnson & Johnson Services Inc. received FDA approval for Darzalex Faspro (daratumumab and hyaluronidase-fish) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for the induction and consolidation treatment of newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation.
The key company operating in the darzalex faspro market is Johnson & Johnson Services Inc.
North America was the largest region in the darzalex faspro market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in darzalex faspro report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the darzalex faspro market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Darzalex Faspro is a medication used to treat multiple myeloma, a type of blood cancer. It works by targeting and depleting CD38-positive cells, thereby boosting the immune system's ability to fight cancer. Unlike traditional intravenous infusions, it is administered as a subcutaneous injection for faster delivery.
The main indications for darzalex faspro are multiple myeloma and AL amyloidosis. Multiple myeloma is a cancer that begins in plasma cells found in bone marrow, disrupting normal blood cell production, leading to bone damage and complications in other organs. Darzalex Faspro is used to effectively manage multiple myeloma and improve patient outcomes. It is administered via oral, parenteral, and other routes and is distributed through various channels, including hospitals, pharmacies, retail pharmacies, online pharmacies, and others. The end users of this medication include hospitals, specialty clinics, homecare settings, and other facilities.
The darzalex faspro market research report is one of a series of new reports that provides darzalex faspro market statistics, including the darzalex faspro industry's global market size, regional shares, competitors with a darzalex faspro market share, detailed darzalex faspro market segments, market trends and opportunities, and any further data you may need to thrive in the darzalex faspro industry. This darzalex faspro market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The darzalex faspro market consists of sales of darzalex faspro 1,800 mg. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to regulatory approvals, the rising prevalence of cancer, the increasing incidence of lifestyle-related diseases, favorable reimbursement policies, and improvements in patient outcomes.
The projected growth in the forecast period is driven by the expanding patient populations, ongoing clinical trials, regulatory expansions, the use of combination therapies, and greater global healthcare access. Key trends during this period include advancements in monoclonal antibody technology, innovations in antibody-drug conjugate development, patient-centric treatments, personalized medicine, and the growing competition from biosimilars.
The increasing incidence of cancer is expected to drive the growth of the darzalex faspro market in the coming years. Cancer encompasses a range of diseases marked by uncontrolled cell growth and spread to other areas of the body. The rising number of cancer cases is influenced by factors such as an aging population, unhealthy lifestyles, environmental exposures, improved detection methods, and genetic factors. Darzalex Faspro plays a significant role in treating cancer, particularly by targeting and depleting CD38-positive cells, which enhances the immune system's ability to combat cancer. This treatment helps manage and reduce the progression of multiple myeloma and other related cancers. For example, the American Cancer Society reported in April 2024 that in 2022, there were 20 million new cancer diagnoses globally, with 9.7 million cancer-related deaths. By 2050, new cancer cases are expected to increase to 35 million. As a result, the growing prevalence of cancer will likely drive the darzalex faspro market forward.
The expansion of global healthcare infrastructure is also expected to contribute to the growth of the darzalex faspro market. Healthcare infrastructure encompasses the necessary structures, resources, and systems required to provide healthcare services. Key drivers of this expansion include an aging global population, the rise in chronic diseases, and advancements in medical technology. Improved healthcare infrastructure is essential for patients who require Darzalex Faspro, as it facilitates access to trained professionals who can administer the subcutaneous injection in outpatient settings, reducing the need for long hospital stays. For instance, according to Cross River Therapy's statistics in September 2024, the U.S. pharmaceutical industry generated $550 billion in revenue in 2021, with Americans spending $576.9 billion on medicine. Projected spending is expected to rise to $605-$635 billion by 2025, highlighting how healthcare infrastructure growth supports the darzalex faspro market.
A key trend in the darzalex faspro market is the focus on regulatory advancements for combination treatments, particularly quadruplet therapy, which is expected to improve treatment outcomes for multiple myeloma patients. Quadruplet therapy involves using four different medications, each targeting different aspects of the disease. In July 2024, Johnson & Johnson Services Inc. received FDA approval for Darzalex Faspro (daratumumab and hyaluronidase-fish) in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for the induction and consolidation treatment of newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation.
The key company operating in the darzalex faspro market is Johnson & Johnson Services Inc.
North America was the largest region in the darzalex faspro market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in darzalex faspro report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the darzalex faspro market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Darzalex Faspro is a medication used to treat multiple myeloma, a type of blood cancer. It works by targeting and depleting CD38-positive cells, thereby boosting the immune system's ability to fight cancer. Unlike traditional intravenous infusions, it is administered as a subcutaneous injection for faster delivery.
The main indications for darzalex faspro are multiple myeloma and AL amyloidosis. Multiple myeloma is a cancer that begins in plasma cells found in bone marrow, disrupting normal blood cell production, leading to bone damage and complications in other organs. Darzalex Faspro is used to effectively manage multiple myeloma and improve patient outcomes. It is administered via oral, parenteral, and other routes and is distributed through various channels, including hospitals, pharmacies, retail pharmacies, online pharmacies, and others. The end users of this medication include hospitals, specialty clinics, homecare settings, and other facilities.
The darzalex faspro market research report is one of a series of new reports that provides darzalex faspro market statistics, including the darzalex faspro industry's global market size, regional shares, competitors with a darzalex faspro market share, detailed darzalex faspro market segments, market trends and opportunities, and any further data you may need to thrive in the darzalex faspro industry. This darzalex faspro market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The darzalex faspro market consists of sales of darzalex faspro 1,800 mg. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Darzalex Faspro Market Characteristics4. Darzalex Faspro Market Trends and Strategies5. Darzalex Faspro Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Darzalex Faspro Pricing Analysis & Forecasts30. Global Darzalex Faspro Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Darzalex Faspro Market32. Recent Developments in the Darzalex Faspro Market
3. Darzalex Faspro Market Biologic Drug Characteristics
6. Global Darzalex Faspro Growth Analysis and Strategic Analysis Framework
8. Darzalex Faspro Market Segmentation
9. Global Darzalex Faspro Epidemiology of Clinical Indications
10. Darzalex Faspro Market Regional and Country Analysis
11. Asia-Pacific Darzalex Faspro Market
12. China Darzalex Faspro Market
13. India Darzalex Faspro Market
14. Japan Darzalex Faspro Market
15. Australia Darzalex Faspro Market
16. South Korea Darzalex Faspro Market
17. Western Europe Darzalex Faspro Market
18. UK Darzalex Faspro Market
19. Germany Darzalex Faspro Market
20. France Darzalex Faspro Market
21. Eastern Europe Darzalex Faspro Market
22. North America Darzalex Faspro Market
23. USA Darzalex Faspro Market
24. Canada Darzalex Faspro Market
25. South America Darzalex Faspro Market
26. Middle East Darzalex Faspro Market
27. Africa Darzalex Faspro Market
28. Darzalex Faspro Market Competitive Landscape and Company Profiles
29. Global Darzalex Faspro Market Pipeline Analysis
33. Darzalex Faspro Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Darzalex Faspro Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on darzalex faspro market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for darzalex faspro? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The darzalex faspro market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Indication: Multiple Myeloma; AL Amyloidosis2) by Route of Administration: Oral; Parenteral; Other Route of Administration
3) by Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channel
4) by End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
Key Companies Mentioned: Johnson & Johnson Services Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Johnson & Johnson Services Inc.
